Determination of carryover and contamination for mass spectrometry-based chromatographic assays
Journal Title: The AAPS Journal - Year 2007, Vol 9, Issue 3
Abstract
The Third American Association of Pharmaceutical Scientists/Food and Drug Administration Bioanalytical Workshop, held in 2006, reviewed and evaluated current practices and proposed that carryover and contamination be assessed not only during the validation of an assay but also during the application of the method in a study. In this article, the potential risks of carryover and contamination in each stage of a bioanalytical method are discussed, to explain to the industry why this recommendation is being made.
Authors and Affiliations
Nicola C. Hughes, Ernest Y. K. Wong, Juan Fan, Navgeet Bajaj
Keywords
Related Articles
- EP ID EP681608
- DOI 10.1208/aapsj0903042
- Views 58
- Downloads 0
Role of MRP4 and MRP5 in biology and chemotherapy
Nucleotide efflux (especially cyclic nucleotides) from a variety of mammalian tissues, bacteria, and lower eukaryotes has been studied for several decades. However, the molecular identity of these nucleotide efflux trans...
A new equivalence based metric for predictive check to qualify mixed-effects models
Activation of G-proteins in brain by endogenous and exogenous cannabinoids
The biological response to cannabinoid agonist begins when the agonist-bound receptor activates G-protein Gα subunits, thus initiating a cascade of signal transduction pathways. For this reason, information about...
Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): In vitro evaluation of efficacy and toxicity
Patients undergoing anticoagulation with heparin or low molecular weight heparin (LMWH) require a superior antidote that possesses more selective biological actions and a better safety profile than protamine. We had prev...
Evaluation of Methods for Estimating Time to Steady State with Examples from Phase 1 Studies
An overview is provided of the methodologies used in determining the time to steady state for Phase 1 multiple dose studies. These methods include NOSTASOT (no-statistical-significance-of-trend), Helmert contrasts, splin...